Timely Filing Limits by Payer for Infusion Claims and Appeals
Infusion practices must track each payer's exact filing deadline to avoid permanent denials.
A clean infusion claim, correctly coded and fully authorized, can still be denied for reason code CO-29 if it crosses the finish line one day late. Reducing denials that recur from the same payers starts with knowing each payer's exact window and understanding which infusion-specific delays eat into it fastest.
Why infusion practices face a structurally shorter filing runway
A denial carrying reason code CO-29 means the claim arrived after the payer's deadline, and in nearly all cases, that denial is permanent. The revenue is written off regardless of whether the medical necessity was sound or the coding was perfect. That outcome is what makes timely filing different from every other category of denial infusion billers deal with, and it's why the mechanics behind it deserve more attention than they usually get.
Infusion claims carry an upstream cycle that most specialties never have to manage before a claim can even be built. A prior authorization dispute, a J-code unit correction, or an NCCI hierarchy error caught after submission can reset or extend the coding cycle by days or sometimes weeks, and that time comes directly out of the filing window, not from some separate buffer.
A denied buy-and-bill biologic claim illustrates the compounding risk clearly. Correcting it may require a corrected NDC, corrected units, a corrected modifier, and in some cases a new reauthorization, all before a corrected claim can even be sent. The practical result: an infusion practice can reach day 85 of a 90-day filing window still untangling a claim that a generalist practice would have submitted by day 10. That gap is the entire argument for why infusion billing needs its own filing discipline, distinct from standard E&M or procedure billing.
How timely filing deadlines are measured
Before any payer-specific deadline means anything, the mechanics of how that clock starts, stops, and resets need to be nailed down. Getting this wrong on a multi-day infusion encounter can mean a claim appears to have more runway than it actually does.
A rejected claim does not stop the clock. A claim bounced before entering adjudication, because of missing or invalid data, is still sitting outside the payer's system as far as the deadline is concerned, even though the billing team may believe it was "submitted on time." This distinction gets missed constantly, and it is the source of a lot of silent deadline breaches that nobody notices until the appeal window has also closed.
Secondary claims add another layer. And the term "timely filing" itself applies separately to initial claims and to appeals of denied claims: some payers set identical windows for both, others set completely different ones, a distinction that matters enormously once a denial actually happens.
CMS Change Request 12909, a recent regulatory shift, says that if a correction just supplements information already on a timely-filed claim, the 12-month window no longer binds it, and administrative finality and reopening rules apply instead. The correct remedy is a reopening request, and only where a valid CMS exception exists, not a standard reconsideration.
Initial claim filing deadlines for the payers most common in infusion panels
Filing deadlines across a typical infusion payer panel range from 90 days to 24 months, and that spread is wide, so applying one mental model across every payer will cost a practice money.
Medicare sets the most uniform standard in the group. Every MAC follows this same 12-month limit, with no contractor extending beyond a year. The exceptions are narrow: administrative error by a Medicare contractor or HHS employee, retroactive Medicare entitlement, or a state Medicaid agency recoupment six months or more after the fact. Services furnished in calendar year 2026 must be filed by December 31, 2027 at the outer boundary, but that extended window applies only to those narrow exception categories, not to routine late submissions.
Medicare Advantage plans complicate the picture because they set their own deadlines through provider participation agreements. CMS sets a regulatory floor of 12 months for non-contracted providers under 42 CFR § 422.520, but contracted deadlines are often far shorter, and they run around 90 days. An infusion practice billing an MA plan under the assumption that Medicare's 12-month rule applies can miss a 90-day contracted deadline on a high-dollar drug claim, so each MA contract needs to be checked individually.
Commercial payers vary widely and sometimes within their own brand. GEHA allows 365 days, running through December 31 of the year following the year of service; Harvard Pilgrim Health Care holds to 90 days; and Magellan allows only 60 days, which matters if a practice bills any behavioral health-adjacent infusion services.
Government and quasi-government payers each run their own logic. Tricare gives participating providers 365 days, and non-participating providers or patients get 365 days from the date of service or from notification of authorization, whichever applies; Tricare for Life allows 365 days from the Medicare EOB date when Medicare is primary. OWCP, the federal workers' compensation program, allows one year after the end of the calendar year in which the service was provided, or one year after the end of the calendar year in which the claim was first accepted as compensable by OWCP, whichever is later, with submissions going through OWCP's EDI gateway or on a CMS-1500 form.
Medicaid has no single national deadline. Windows range from 90 days to 12 months depending on the state and on whether the claim runs through fee-for-service Medicaid or a Medicaid managed care organization. On the short end, New York and Massachusetts both allow 90 days, and Texas allows 95. On the longer end, Florida and Hawaii Medicaid both allow 12 months, and California's Medi-Cal program allows roughly 180 days. Several states shortened their Medicaid filing windows in 2025 and 2026, so current state billing manuals need to be the final check.
Self-funded plans administered under the UMR brand add one more wrinkle. Filing requirements are set by the self-funded employer and the specific provider contract, not by UMR itself, with 90 days being the tightest window commonly applied. Two employer groups can carry the same UMR logo and network and still run entirely different deadlines, so the UMR timely filing limit belongs at the employer group level in any payer matrix, never at the brand level.
VA Community Care rounds out the list with a 180-day window from date of service.
Appeal filing deadlines, which diverge sharply from initial claim windows and catch infusion teams unprepared
Appeal deadlines run on a different clock than initial filing deadlines, and treating an appeal as a simple extension of the original filing window is one of the most expensive mistakes in infusion denial management. The appeal clock starts on the date of the EOB or ERA, not the date of service, and it starts running the moment the denial is issued, regardless of when the billing team actually reviews it.
Medicare's appeal structure has five levels, each with its own window. The appeal structure's first two levels allow 120 days from the MSN or ERA for Level 1 Redetermination and 180 days from the redetermination decision for Level 2 Reconsideration. Level 3, an ALJ hearing, allows 60 days from the reconsideration decision. Most Medicare denials get resolved at Level 1 or Level 2, and the full five-level structure tends to matter most for high-dollar drug claims that warrant escalation. For a timely filing denial specifically, standard appeal isn't available at all, and the only path forward is a reopening request where a valid CMS exception applies.
Commercial payers set shorter, tighter windows. Anthem BCBS allows 60 days from the denial for a first appeal and another 60 days from that decision for a second appeal, with other BCBS state licensees setting their own variations.
UnitedHealthcare's commercial appeal window runs 65 calendar days, separate from its 90-day reconsideration process, and that gap is a specific trap for infusion billing teams. External review, available after internal appeals are exhausted, runs on its own separate filing window and matters most for site-of-care and medical necessity denials on biologic infusions.
The infusion-specific denial patterns that most frequently trigger timely filing risk before a corrected claim can be built
Certain denial categories recur constantly in infusion billing, and they happen to be the same categories that take the longest to correct. That overlap is why timely filing risk concentrates so heavily in this specialty rather than spreading evenly across billing error types.
J-code unit errors sit at the top of the list. Medicare and Medicaid drug claims also require a matching NDC number. A missing or mismatched NDC triggers a rejection rather than a denial, so the filing clock keeps running the whole time the claim sits unresolved. The JW modifier for drug waste adds another failure point: when a single-dose vial generates discarded drug, that modifier has to be documented and billed, and missing it when waste exists can create a compliance gap or an underbilling that looks like a routine posting error until a remit audit catches it.
CPT administration hierarchy errors are the single most common coding failure in infusion billing, especially when a multi-drug encounter involves three to five agents in oncology or rheumatology. Fixing a hierarchy error on a complex encounter is rarely a one-line correction. It often means re-sequencing every line on the claim and re-validating the sequence against the administered record, a process that eats days directly out of a 90-day window.
Prior authorization failures carry their own filing risk. For recurring infusion treatments, if an authorization lapses or expires without anyone noticing until after treatment, it creates a retroactive PA problem, and that is far harder to resolve than catching the lapse before the infusion happens.
340B modifier disputes and site-of-care denials add further delay. A J-code unit error combined with a hierarchy mistake on the same claim compounds the correction timeline, and that compounding pushes practices toward day 85 of a 90-day window.
Prior authorization timing and filing windows in recurring infusion treatment cycles
Recurring infusion treatment runs on two calendars at once: the authorization cycle and the filing window, and those two calendars can fall out of sync in ways that create real financial exposure. When they do, a practice either submits a claim for a treatment it can't yet code cleanly, or it holds the claim until authorization resolves, burning filing time it may never get back.
Most infusion medications carry authorization renewals tied to dosing cycles or clinical response updates. An authorization covering eight infusions over six months creates its own recurring authorization calendar, and that calendar has to stay synchronized with the claim submission calendar or the two will drift apart. Even a small delay in renewal disrupts patient scheduling and revenue forecasting at the same time: if the renewal isn't in hand before the next treatment cycle starts, the claim can't be submitted cleanly, and the filing window has already started counting down from the date of service regardless.
The prior authorization burden itself is structural. A first-submission denial rate approaching one in three PA requests makes this worse, because the authorization cycle then often requires a second round of documentation, follow-up, and sometimes a peer-to-peer conversation, and all of that has to finish before the claim is clean. Every step in that second round consumes filing days that don't come back.
State-level policy adds another variable for oncology and specialty infusion providers specifically. The practical conclusion is that revenue cycle control for recurring infusion has to start at scheduling, not at billing. By the time a claim is ready to submit, the authorization runway has already been set by decisions made weeks earlier, and no amount of billing diligence after the fact can recover time that scheduling and authorization teams already spent.
What payer-specific exceptions and good cause arguments can recover a late claim
Exceptions to timely filing deadlines exist, but they are narrow, specific to each payer, and they rarely cover the kinds of infusion billing failures that actually cause late claims. Treating exception arguments as a recovery strategy, rather than a last resort, invites disappointment.
Medicare's exceptions are codified and limited. Prior authorization disputes, J-code correction cycles, and batch submission failures are not enumerated exceptions under Medicare's framework, so you cannot argue that infusion billing complexity itself constitutes good cause.
Commercial payers vary in what they'll accept. Documentation of the exception circumstance has to accompany the resubmission; a bare resubmission without that narrative gets denied on the same original grounds.
Some arguments simply do not work anywhere. The practical conclusion is straightforward: no exception framework reliably covers the delays that cause most late infusion claims, which makes prevention the only strategy a practice can actually depend on.
Building a payer-specific filing calendar that accounts for infusion billing lead time
Infusion billing lead time runs predictably longer than it does in other specialties. Internal submission deadlines need to sit comfortably ahead of the payer's actual limit, with buffer room built in. The payer deadline functions as a hard backstop, not a target to aim for.
The 90-day payers, including UnitedHealthcare, Aetna, many Medicare Advantage plans, and several short-window Medicaid states, demand the tightest internal calendars of the group. A payer matrix built to track these deadlines needs to live at the plan and contract level, not the brand level: a sub-plan, a Medicare Advantage plan, and a state licensee under the same parent payer can each carry their own deadline, and assuming a single brand-wide number invites exactly the kind of miss described earlier with a payer's state-by-state variation.
Aging alerts built around each payer's specific deadline surface at-risk claims while they can still be corrected. A claim at day 70 under a UHC plan needs a different response than one at day 70 under a Tricare plan, but a single aging threshold applied across all payers hides that difference. Recurring infusion schedules make this easier to manage proactively: a patient receiving a biologic every four weeks creates a predictable claim cycle and authorization renewal cycle that can both be scheduled in advance.
For buy-and-bill claims specifically, the full acquisition-to-submission cycle, meaning drug procurement, administration, clinical documentation, coding, and authorization confirmation, should be mapped and timed as a single process. If that cycle routinely runs longer than 30 days, the practice faces structural risk under any 90-day payer window, regardless of how careful the billing team is at the submission stage. Denial pattern tracking organized by payer and root cause, rather than by generic denial code, closes the loop: if J-code unit corrections consistently take two weeks at a specific payer, that correction time can be built directly into the internal deadline calendar instead of being discovered only after a CO-29 denial arrives.
The upstream complexity described throughout this piece, prior authorization disputes, J-code corrections, multi-drug sequencing, is why infusion billing benefits from operational oversight built specifically around these dependencies. Closing that gap between knowing the rule and acting on it in time is the entire argument this piece has been building toward.
